Cognition Disorders Completed Phase 3 Trials for Rivastigmine (DB00989)

IndicationStatusPhase
DBCOND0027877 (Cognition Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00000174Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)Treatment